HR Execs on the Move

Annexon Biosciences

www.annexonbio.com

 
Annexon is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders of the body, brain and eye. The company`s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration) and ANX009 (subcutaneous administration). Annexon is deploying a ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.annexonbio.com
  • 180 Kimball Way 2nd Floor, Suite 200
    South San Francisco, CA USA 94080
  • Phone: 650.822.5500

Executives

Name Title Contact Details

Similar Companies

Kamiya Biomedical Company

Kamiya Biomedical Company is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharmathene

Pharmathene, Inc is a Annapolis, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

New Century Pharmaceuticals

New Century Pharmaceuticals is a Huntsville, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

FOB Synthesis

FOB Synthesis is a Kennesaw, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NanoString

NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research. The company`s technology enables a wide variety of basic research and translational medicine applications. NanoString`s products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection. In 2019, the company launched the GeoMx™ Digital Spatial Profiler enabling highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections.